Studio di Dose-Risposta di ORKA-001 in Pazienti con Psoriasi a Placche da Moderata a Grave (EVERLAST-B)
Studio multicentrico, randomizzato, in doppio cieco, controllato con placebo, per la determinazione della dose di ORKA-001 in partecipanti con psoriasi a placche da moderata a grave
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey, British Columbia, Canada, V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax, Ontario, Canada, L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham, Ontario, Canada, L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough, Ontario, Canada, K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canada, HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec, Quebec, Canada, G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
-
-
Baden-Wuerrtemberg
-
Heidelberg, Baden-Wuerrtemberg, Germania, 69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Germania, 60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim, Lower Saxony, Germania, 48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germania, 24105
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona, Barcelona, Spagna, 08916
- Oruka Therapeutics Investigative Site
-
Barcelona, Barcelona, Spagna, 08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid, Madrid, Spagna, 28002
- Oruka Therapeutics Investigative Site
-
Madrid, Madrid, Spagna, 28046
- Oruka Therapeutics Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock, Arkansas, Stati Uniti, 72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles, California, Stati Uniti, 90045
- Oruka Therapeutics Investigative Site
-
Los Angeles, California, Stati Uniti, 90024
- Oruka Therapeutics Investigative Site
-
San Diego, California, Stati Uniti, 92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami, Florida, Stati Uniti, 33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows, Illinois, Stati Uniti, 60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield, Indiana, Stati Uniti, 46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens, New York, Stati Uniti, 11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Oruka Therapeutics Investigative Site
-
Mason, Ohio, Stati Uniti, 45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97201
- Oruka Therapeutics Investigative Site
-
Portland, Oregon, Stati Uniti, 97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco, Texas, Stati Uniti, 75033
- Oruka Therapeutics Investigative Site
-
Houston, Texas, Stati Uniti, 77004
- Oruka Therapeutics Investigative Site
-
Webster, Texas, Stati Uniti, 77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti, 23502
- Oruka Therapeutics Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: (Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Sperimentale: (Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Sperimentale: (Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Comparatore placebo: (Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
Sperimentale: (Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Sperimentale: (Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Comparatore placebo: (Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Lasso di tempo: Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Lasso di tempo: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Lasso di tempo: Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Lasso di tempo: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Lasso di tempo: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Lasso di tempo: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Lasso di tempo: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Lasso di tempo: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Lasso di tempo: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Lasso di tempo: Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- ORKA-001-114
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .